-$0.72 EPS Expected for Zynerba Pharmaceuticals Inc (ZYNE) This Quarter

Equities research analysts expect Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to post earnings of ($0.72) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Zynerba Pharmaceuticals’ earnings. Zynerba Pharmaceuticals posted earnings of ($0.60) per share in the same quarter last year, which suggests a negative year over year growth rate of 20%. The firm is expected to announce its next earnings results on Monday, March 11th.

According to Zacks, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($3.13) per share for the current fiscal year, with EPS estimates ranging from ($3.18) to ($3.06). For the next financial year, analysts anticipate that the company will report earnings of ($2.61) per share, with EPS estimates ranging from ($2.68) to ($2.57). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.23.

ZYNE has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 target price on shares of Zynerba Pharmaceuticals in a research note on Tuesday, October 2nd. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 6th. Zacks Investment Research lowered Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. Canaccord Genuity lowered their target price on Zynerba Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 3rd. Finally, ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $18.93.

In related news, Director John P. Butler bought 5,000 shares of the stock in a transaction dated Wednesday, August 22nd. The stock was acquired at an average price of $6.43 per share, for a total transaction of $32,150.00. Following the completion of the purchase, the director now owns 5,000 shares in the company, valued at $32,150. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.67% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ZYNE. Wells Fargo & Company MN grew its stake in Zynerba Pharmaceuticals by 19.6% during the 1st quarter. Wells Fargo & Company MN now owns 41,414 shares of the company’s stock valued at $360,000 after purchasing an additional 6,782 shares in the last quarter. Northern Trust Corp grew its stake in Zynerba Pharmaceuticals by 17.3% during the 1st quarter. Northern Trust Corp now owns 167,342 shares of the company’s stock valued at $1,455,000 after purchasing an additional 24,663 shares in the last quarter. BlackRock Inc. grew its stake in Zynerba Pharmaceuticals by 5.4% during the 1st quarter. BlackRock Inc. now owns 715,185 shares of the company’s stock valued at $6,216,000 after purchasing an additional 36,488 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Zynerba Pharmaceuticals by 385.6% during the 1st quarter. JPMorgan Chase & Co. now owns 12,217 shares of the company’s stock valued at $106,000 after purchasing an additional 9,701 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Zynerba Pharmaceuticals during the 1st quarter valued at approximately $903,000. Hedge funds and other institutional investors own 14.08% of the company’s stock.

ZYNE stock opened at $5.95 on Friday. Zynerba Pharmaceuticals has a 1 year low of $5.03 and a 1 year high of $15.14. The stock has a market capitalization of $102.22 million, a PE ratio of -2.40 and a beta of 4.49.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Recommended Story: What is Cost of Capital?

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply